CL2015003690A1 - Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. - Google Patents

Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.

Info

Publication number
CL2015003690A1
CL2015003690A1 CL2015003690A CL2015003690A CL2015003690A1 CL 2015003690 A1 CL2015003690 A1 CL 2015003690A1 CL 2015003690 A CL2015003690 A CL 2015003690A CL 2015003690 A CL2015003690 A CL 2015003690A CL 2015003690 A1 CL2015003690 A1 CL 2015003690A1
Authority
CL
Chile
Prior art keywords
pridopidine
huntington
disease
prepare
salt
Prior art date
Application number
CL2015003690A
Other languages
English (en)
Spanish (es)
Inventor
Merav Bassan
Eli Eyal
Esther Lukasiewicz Hagai
Teige Wickenberg Anna Kristina Sveinsdotter
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of CL2015003690A1 publication Critical patent/CL2015003690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2015003690A 2013-06-21 2015-12-21 Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. CL2015003690A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
CL2015003690A1 true CL2015003690A1 (es) 2016-10-28

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003690A CL2015003690A1 (es) 2013-06-21 2015-12-21 Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.

Country Status (24)

Country Link
US (1) US10322119B2 (enExample)
EP (1) EP3010506B1 (enExample)
JP (1) JP2016523862A (enExample)
KR (1) KR102316933B1 (enExample)
CN (1) CN105592848A (enExample)
AU (1) AU2014281414A1 (enExample)
BR (1) BR112015029918A2 (enExample)
CA (1) CA2913781C (enExample)
CL (1) CL2015003690A1 (enExample)
DK (1) DK3010506T3 (enExample)
EA (1) EA201690069A1 (enExample)
ES (1) ES2879631T3 (enExample)
HK (1) HK1221646A1 (enExample)
HU (1) HUE054783T2 (enExample)
IL (1) IL242804B (enExample)
MX (1) MX384234B (enExample)
PE (2) PE20160195A1 (enExample)
PH (1) PH12015502691A1 (enExample)
PL (1) PL3010506T3 (enExample)
SG (1) SG11201509729YA (enExample)
TW (1) TW201529069A (enExample)
UA (1) UA122999C2 (enExample)
UY (1) UY35624A (enExample)
WO (1) WO2014205229A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EA201691454A1 (ru) * 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10603311B2 (en) * 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CN110012661A (zh) * 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
DK3504187T3 (da) * 2016-08-24 2025-04-14 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af funktionel tilbagegang
ES3031271T3 (en) 2016-09-15 2025-07-07 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett
BR112019015000A2 (pt) 2017-01-20 2020-04-07 Prilenia Neurotherapeutics Ltd. uso de pridopidina para o tratamento da síndrome do x frágil
AU2018317346B2 (en) 2017-08-14 2021-08-26 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
CN111278431A (zh) * 2017-08-30 2020-06-12 普瑞尼亚神经治疗有限公司 普利多匹定的高浓度剂型
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
AU2020218158B2 (en) 2019-02-04 2023-08-03 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
AU2020293739B2 (en) * 2019-06-12 2023-11-30 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
JP7432711B2 (ja) * 2019-09-17 2024-02-16 エフ． ホフマン－ラ ロシュ アーゲー 動作障害患者に対する個別化医療の改善
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
PL1802573T3 (pl) 2004-10-13 2017-03-31 Teva Pharmaceuticals International Gmbh Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) * 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US20140088145A1 (en) 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
WO2014052933A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
EA201691454A1 (ru) 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
DK3504187T3 (da) * 2016-08-24 2025-04-14 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af funktionel tilbagegang
ES3031271T3 (en) 2016-09-15 2025-07-07 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
IL242804B (en) 2022-02-01
PL3010506T3 (pl) 2021-11-02
WO2014205229A8 (en) 2015-04-09
EP3010506A4 (en) 2017-02-08
KR20160055122A (ko) 2016-05-17
CN105592848A (zh) 2016-05-18
MX2015017307A (es) 2016-08-03
CA2913781C (en) 2022-05-10
EA201690069A1 (ru) 2016-06-30
US20140378508A1 (en) 2014-12-25
EP3010506B1 (en) 2021-05-12
WO2014205229A1 (en) 2014-12-24
TW201529069A (zh) 2015-08-01
US10322119B2 (en) 2019-06-18
CA2913781A1 (en) 2014-12-24
SG11201509729YA (en) 2015-12-30
AU2014281414A1 (en) 2016-01-21
UA122999C2 (uk) 2021-02-03
DK3010506T3 (da) 2021-07-12
BR112015029918A2 (pt) 2017-07-25
PE20170302A1 (es) 2017-03-31
KR102316933B1 (ko) 2021-10-26
ES2879631T3 (es) 2021-11-22
PE20160195A1 (es) 2016-05-14
UY35624A (es) 2015-01-30
JP2016523862A (ja) 2016-08-12
HK1221646A1 (zh) 2017-06-09
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
EP3010506A1 (en) 2016-04-27
HUE054783T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
CL2016002971A1 (es) Combinación.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
ECSP16096831A (es) Derivados de naftiridinadiona
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
DOP2015000175A (es) Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2016003230A1 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas